Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats

Teuku Heriansyah; Titin Andri Wihastuti; Kenty Wantri Anita; Agustin Iskandar; Riski Bagus Suhendra; Patan Ahmad Setiabudi; Lintang Widya Sishartami

doi:10.5455/njppp.2015.5.2909201580

2026, Vol: 16, Issue: 1

16 / 1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 29 Dec 2015

Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58

doi: 10.5455/njppp.2015.5.2909201580

Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami.

Cited By:12

Abstract
Background: Atherosclerosis is a chronic inflammation disease that is caused by the interaction between monocyte and endothelial injury in tunica intima. One of the major factor of atherosclerosis is dyslipidemia. Chronic dyslipidemia, especially hypercholesterolemia, can directly alter endothelial cell through reactive oxygen species (ROS) production that oxidizes low-density lipoprotein (LDL) to become oxidized LDL (Ox-LDL). Proinflammatory cytokines, the products of perivascular adipocyte tissue (PVAT), may draw macrophage. Macrophage then engulfs Ox-LDL and becomes foam cell within tunica intima. Lipoprotein-associated phospholipase A2 (Lp-pLA2) is an enzyme that cleaves Ox-LDL to become proatherosclerotic products. Darapladib, an Lp-pLA2 inhibitor, is expected to inhibit atherosclerotic lesion progressivity.

Aims and Objective: To know the effects of darapladib on Ox-LDL level, PVAT thickness, and foam cell number.

Materials and Methods: This study used in vivo posttest controlled group design with two time series. Thirty male SpragueDawley rats divided into two group based on time series (8 weeks and 16 weeks). Each time serial was divided into three groups which were: standard diet group ;high-fat diet group; and dyslipidemia model with darapladib administration group with dose of 200 mg/200 g body weight (BW). The parameters that was measured in this study were lipid profile [total cholesterol, LDL/very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL)], Ox-LDL level, number of foam cells, and PVAT thickness.

Result: Ox-LDL level and foam cell number decreased significantly (p = 0.000 and p = 0.005, respectively), while PVAT thickness did not show significant difference (p = 0.912).

Conclusion: In this, study, it has been proven that darapladib decreases Ox-LDL levels and foam cell numbers but not in PVAT thickness, even though a decreasing pattern was observed histologically. Further study needed to know the optimum dosage of darapladib administration.

Key words: Darapladib; Lp-PLA2; Ox-LDL; Foam Cell; PVAT; Dyslipidemia

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Teuku Heriansyah Articles by Titin Andri Wihastuti Articles by Kenty Wantri Anita Articles by Agustin Iskandar Articles by Riski Bagus Suhendra Articles by Patan Ahmad Setiabudi Articles by Lintang Widya Sishartami
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Heriansyah T, Wihastuti TA, Anita KW, Iskandar A, Suhendra RB, Setiabudi PA, Sishartami LW. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580

Web Style

Heriansyah T, Wihastuti TA, Anita KW, Iskandar A, Suhendra RB, Setiabudi PA, Sishartami LW. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. https://www.njppp.com/?mno=203195 [Access: November 01, 2025]. doi:10.5455/njppp.2015.5.2909201580

AMA (American Medical Association) Style

Heriansyah T, Wihastuti TA, Anita KW, Iskandar A, Suhendra RB, Setiabudi PA, Sishartami LW. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580

Vancouver/ICMJE Style

Heriansyah T, Wihastuti TA, Anita KW, Iskandar A, Suhendra RB, Setiabudi PA, Sishartami LW. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol. (2016), [cited November 01, 2025]; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580

Harvard Style

Heriansyah, T., Wihastuti, . T. A., Anita, . K. W., Iskandar, . A., Suhendra, . R. B., Setiabudi, . P. A. & Sishartami, . L. W. (2016) Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. Natl J Physiol Pharm Pharmacol, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580

Turabian Style

Heriansyah, Teuku, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, and Lintang Widya Sishartami. 2016. Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. National Journal of Physiology, Pharmacy and Pharmacology, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580

Chicago Style

Heriansyah, Teuku, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, and Lintang Widya Sishartami. "Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 52-58. doi:10.5455/njppp.2015.5.2909201580

MLA (The Modern Language Association) Style

Heriansyah, Teuku, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, and Lintang Widya Sishartami. "Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats." National Journal of Physiology, Pharmacy and Pharmacology 6.1 (2016), 52-58. Print. doi:10.5455/njppp.2015.5.2909201580

APA (American Psychological Association) Style

Heriansyah, T., Wihastuti, . T. A., Anita, . K. W., Iskandar, . A., Suhendra, . R. B., Setiabudi, . P. A. & Sishartami, . L. W. (2016) Atherogenesis inhibition by darapladib administration in dyslipidemia model SpragueDawley rats. National Journal of Physiology, Pharmacy and Pharmacology, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article